Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis

69Citations
Citations of this article
119Readers
Mendeley users who have this article in their library.

Abstract

Context: The active metabolite of vitamin D, 1,25-dihydroxyvitamin D [1,25(OH) 2D], is a potent modulator of immune cells in vitro. Objective: Our objective was to determine whether the sun-dependent nutrient, cholecalciferol, can alter disease-associated cellular immune abnormalities in patients with multiple sclerosis (MS). Design: This was an open-label, 12-month, randomized controlled trial. Setting: Patients with MS were recruited from the MS Clinic at St. Michael's Hospital, Toronto. Patients: Forty-nine patientswerematched(for age, sex, disease duration, disease-modifying drug, and disability) and enrolled (treated n = 25; control n = 24). Four patients were lost to follow-up (n = 2 from each group). Intervention: Treated patients received increasing doses of cholecalciferol (4,000-40,000 IU/d) plus calcium (1200 mg/d), followed by equilibration to a moderate, physiological intake (10,000 IU/d). Control patients did not receive supplements. Main Outcome Measures: At enrollment and at 12 months, peripheral blood mononuclear cell (PBMC) proliferative responses to disease-associated, MS-relevant, and control antigens were measured, along with selected serum biochemical markers. Results: At 12 months, mean serum 25-hydroxyvitamin D [25(OH)D] concentrations were 83 ± 35 nmol/liter and 179 ± 76 nmol/liter in control and treated participants, respectively (paired t, P <0.001). Serum 1,25(OH) 2D did not differ between baseline and 1 yr. In treated patients, 12-month PBMCproliferative responses to neuron antigens myelin basic protein and exon-2 were suppressed (P = 0.002). In controls, there were no significant changes in disease-associated PBMC responsiveness. There were no significant differences between groups in levels of selected biomarkers. Interpretation: MS-associated, abnormal T cell reactivities were suppressed in vivo by cholecalciferol at serum 25(OH)D concentrations higher than 100 nmol/liter. Copyright © 2011 by The Endocrine Society.

Cite

CITATION STYLE

APA

Kimball, S., Vieth, R., Dosch, H. M., Bar-Or, A., Cheung, R., Gagne, D., … Burton, J. M. (2011). Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. Journal of Clinical Endocrinology and Metabolism, 96(9), 2826–2834. https://doi.org/10.1210/jc.2011-0325

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free